STING1 and neoplasm: In addition to M1-like TAMs, we do not exclude the contributions of other cell types to the efficacy of the combination therapy, e.g. DCs and endothelial cells, which can also be responders to a STING agonist in eliciting anti-tumor immunity (42, 43).